Alliance spends as profits grow

SPECIALITY pharmaceutical group Alliance said yesterday that its first half sales were £24.3m, an increase of £1m from last year’s figures.

As pre-tax profits for the first six months hit £7m, the firm also said it had expanded its portfolio by buying the UK marketing rights of six products from Beacon Pharmaceuticals.

The new products garnered sales of around £2m for Beacon last year, mainly from acne treatment Rizuderm.

Alliance is funding the acquisition through a loan from its £20m revolving credit facility.